Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dolasetron mesylate
Drug ID BADD_D00703
Description Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Indications and Usage For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
Marketing Status Discontinued
ATC Code A04AA04
DrugBank ID DB00757
KEGG ID D00725
MeSH ID C060344
PubChem ID 3033817
TTD Drug ID D00YLW
NDC Product Code 30698-220; 62147-0094; 62147-0095; 63827-1007
Synonyms dolasetron | 1H-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)- | octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl 1H-indole-3-carboxylate | indole-3-carboxylic acid, ester with (8R)-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one | dolasetron mesylate | dolasetron mesylate monohydrate | 1H-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester methanesulfonate | dolasetron mesilate monohydrate | 1H-indole-3-carboxylic acid, (6R,9AS)-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1) | Anzemet | MDL 73,147EF | MDL-73147EF | MDL 73147EF
Chemical Information
Molecular Formula C20H24N2O6S
CAS Registry Number 115956-13-3
SMILES CS(=O)(=O)O.C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.01.003--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anxiety19.06.02.002--
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Bronchospasm22.03.01.004; 10.01.03.012--
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Headache17.14.01.001--
Hypotension24.06.03.002--
Myalgia15.05.02.001--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Paraesthesia17.02.06.005--
Rash23.03.13.001--Not Available
Sinus arrhythmia02.03.03.008--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.06.008--Not Available
Urinary tract obstruction20.08.01.004--
The 1th Page    1    Total 1 Pages